ClinicaliQ Trial Snapshot
- Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer — Active Not Recruiting • Phase III • Oncology • NCT05445778.
- GLORIOSA Trial Summary.
- Adding mirvetuximab soravtansine to bevacizumab improves outcomes in platinum-sensitive ovarian cancer with high folate receptor expression.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
GLORIOSA is a Phase 3 multicenter, open label study designed to evaluate the safety and efficacy of mirvetuximab Soravtansine + Bevacizumab as maintenance therapy in participants with platinum-sensitive ovarian, primary peritoneal or fallopian tube cancers with high folate receptor-alpha (FRα) expression. Conditions: Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer Interventions: Mirvetuximab soravtansine plus Bevacizumab, Bevacizumab Lead Sponsor: AbbVie Planned Enrollment: 520 participants